Skip to main content
Scientific publications

At Day One, we use the power of leading-edge science to improve patient outcomes.

We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
October 2021
FIRELIGHT: DAY101-102a, a phase 2 subprotocol of DAY101 monotherapy for patients with recurrent, progressive, or refractory solid tumors with an activating BRAF gene fusion
Mehmi I, Lourdes L, Cornelio I, Blackman S, Barry E, Drexel M, Kondo A, Kummar S
18th International Congress of the Society for Melanoma Research
October 2021
Prolonged complete response to the pan-RAF inhibitor DAY101 in a patient with an NRAS-mutated acral lentiginous melanoma
Medina T, Barry E, Raju S, Blackman S, Gonzalez R
18th International Congress of the Society for Melanoma Research
April 2021
Pan-RAF inhibitor DAY101 exhibits preclinical activity in preclinical tumor models harboring BRAF alterations beyond BRAF V600E mutation
Venetsanakos E, Preigh M, Hou J, Cox MC, Blackman SC
Pan-RAF inhibitor DAY101 exhibits preclinical activity in preclinical tumor models harboring BRAF alterations beyond BRAF V600E mutation. Abstract 1481. Presented at the American Association for Cancer Research Annual Meeting, April 10-15, 2021.